PURPOSE: Constitutional mismatch repair deficiency syndrome (CMMRD) is a lethal cancer predisposition syndrome characterized by early-onset synchronous and metachronous multiorgan tumors. We designed a surveillance protocol for early tumor detection in these individuals. PATIENTS AND METHODS: Data were collected from patients with confirmed CMMRD who were registered in the International Replication Repair Deficiency Consortium. Tumor spectrum, efficacy of the surveillance protocol, and malignant transformation of low-grade lesions were examined for the entire cohort. Survival outcomes were analyzed for patients followed prospectively from the time of surveillance implementation. RESULTS: A total of 193 malignant tumors in 110 patients were identified. Median age of first cancer diagnosis was 9.2 years (range: 1.7-39.5 years). For patients undergoing surveillance, all GI and other solid tumors, and 75% of brain cancers were detected asymptomatically. By contrast, only 16% of hematologic malignancies were detected asymptomatically (P < .001). Eighty-nine patients were followed prospectively and used for survival analysis. Five-year overall survival (OS) was 90% (95% CI, 78.6 to 100) and 50% (95% CI, 39.2 to 63.7) when cancer was detected asymptomatically and symptomatically, respectively (P = .001). Patient outcome measured by adherence to the surveillance protocol revealed 4-year OS of 79% (95% CI, 54.8 to 90.9) for patients undergoing full surveillance, 55% (95% CI, 28.5 to 74.5) for partial surveillance, and 15% (95% CI, 5.2 to 28.8) for those not under surveillance (P < .0001). Of the 64 low-grade tumors detected, the cumulative likelihood of transformation from low-to high-grade was 81% for GI cancers within 8 years and 100% for gliomas in 6 years. CONCLUSION: Surveillance and early cancer detection are associated with improved OS for individuals with CMMRD.

• MeSH
• časná detekce nádoru metody   MeSH
• dědičné nádorové syndromy diagnóza   epidemiologie   metabolismus   mortalita   MeSH
• dítě MeSH
• dospělí MeSH
• enzymy opravy DNA nedostatek   MeSH
• kolorektální nádory diagnóza   epidemiologie   metabolismus   mortalita   MeSH
• lidé MeSH
• míra přežití MeSH
• mladiství MeSH
• mladý dospělý MeSH
• nádory mozku diagnóza   epidemiologie   metabolismus   mortalita   MeSH
• následné studie MeSH
• oprava chybného párování bází DNA * MeSH
• předškolní dítě MeSH
• prognóza MeSH
• prospektivní studie MeSH
• surveillance populace MeSH
• Check Tag
• dítě MeSH
• dospělí MeSH
• lidé MeSH
• mladiství MeSH
• mladý dospělý MeSH
• mužské pohlaví MeSH
• předškolní dítě MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Geografické názvy
• Spojené státy americké epidemiologie   MeSH
• Názvy látek
• enzymy opravy DNA MeSH

Renal cell carcinoma (RCC) subtypes are increasingly being discerned via their molecular underpinnings. Frequently this can be correlated to histologic and immunohistochemical surrogates, such that only simple targeted molecular assays, or none at all, are needed for diagnostic confirmation. In clear cell RCC, VHL mutation and 3p loss are well known; however, other genes with emerging important roles include SETD2, BAP1, and PBRM1, among others. Papillary RCC type 2 is now known to include likely several different molecular entities, such as fumarate hydratase (FH) deficient RCC. In MIT family translocation RCC, an increasing number of gene fusions are now described. Some TFE3 fusion partners, such as NONO, GRIPAP1, RBMX, and RBM10 may show a deceptive fluorescence in situ hybridization result due to the proximity of the genes on the same chromosome. FH and succinate dehydrogenase deficient RCC have implications for patient counseling due to heritable syndromes and the aggressiveness of FH-deficient RCC. Immunohistochemistry is increasingly available and helpful for recognizing both. Emerging tumor types with strong evidence for distinct diagnostic entities include eosinophilic solid and cystic RCC and TFEB/VEGFA/6p21 amplified RCC. Other emerging entities that are less clearly understood include TCEB1 mutated RCC, RCC with ALK rearrangement, renal neoplasms with mutations of TSC2 or MTOR, and RCC with fibromuscular stroma. In metastatic RCC, the role of molecular studies is not entirely defined at present, although there may be an increasing role for genomic analysis related to specific therapy pathways, such as for tyrosine kinase or MTOR inhibitors.

• MeSH
• dědičné nádorové syndromy diagnóza   genetika   metabolismus   patologie   MeSH
• hybridizace in situ fluorescenční MeSH
• imunohistochemie MeSH
• karcinom z renálních buněk diagnóza   genetika   metabolismus   patologie   MeSH
• laboratorní medicína MeSH
• lidé MeSH
• metastázy nádorů MeSH
• molekulární patologie MeSH
• mutace MeSH
• nádorové biomarkery * genetika   metabolismus   MeSH
• nádory ledvin diagnóza   genetika   metabolismus   patologie   MeSH
• prognóza MeSH
• společnosti lékařské MeSH
• urologie MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• konsensus - konference MeSH
• směrnice pro lékařskou praxi MeSH
• Názvy látek
• nádorové biomarkery * MeSH

PURPOSE: Constitutional mismatch repair deficiency (CMMRD) is a highly penetrant cancer predisposition syndrome caused by biallelic mutations in mismatch repair (MMR) genes. As several cancer syndromes are clinically similar, accurate diagnosis is critical to cancer screening and treatment. As genetic diagnosis is confounded by 15 or more pseudogenes and variants of uncertain significance, a robust diagnostic assay is urgently needed. We sought to determine whether an assay that directly measures MMR activity could accurately diagnose CMMRD. PATIENTS AND METHODS: In vitro MMR activity was quantified using a 3'-nicked G-T mismatched DNA substrate, which requires MSH2-MSH6 and MLH1-PMS2 for repair. We quantified MMR activity from 20 Epstein-Barr virus-transformed lymphoblastoid cell lines from patients with confirmed CMMRD. We also tested 20 lymphoblastoid cell lines from patients who were suspected for CMMRD. We also characterized MMR activity from patients with neurofibromatosis type 1, Li-Fraumeni syndrome, polymerase proofreading-associated cancer syndrome, and Lynch syndrome. RESULTS: All CMMRD cell lines had low MMR activity (n = 20; mean, 4.14 ± 1.56%) relative to controls (n = 6; mean, 44.00 ± 8.65%; P < .001). Repair was restored by complementation with the missing protein, which confirmed MMR deficiency. All cases of patients with suspected CMMRD were accurately diagnosed. Individuals with Lynch syndrome (n = 28), neurofibromatosis type 1 (n = 5), Li-Fraumeni syndrome (n = 5), and polymerase proofreading-associated cancer syndrome (n = 3) had MMR activity that was comparable to controls. To accelerate testing, we measured MMR activity directly from fresh lymphocytes, which yielded results in 8 days. CONCLUSION: On the basis of the current data set, the in vitro G-T repair assay was able to diagnose CMMRD with 100% specificity and sensitivity. Rapid diagnosis before surgery in non-neoplastic tissues could speed proper therapeutic management.

• MeSH
• dědičné nádorové syndromy diagnóza   genetika   metabolismus   MeSH
• DNA vazebné proteiny genetika   metabolismus   MeSH
• enzymy opravy DNA genetika   metabolismus   MeSH
• fenotyp MeSH
• genetická predispozice k nemoci MeSH
• genetické testování * MeSH
• homolog 2 proteinu MutS genetika   metabolismus   MeSH
• kolorektální nádory diagnóza   genetika   metabolismus   MeSH
• lidé MeSH
• mismatch repair endonukleáza PMS2 genetika   metabolismus   MeSH
• mutace * MeSH
• MutL homolog 1 genetika   metabolismus   MeSH
• nádorové biomarkery genetika   metabolismus   MeSH
• nádorové buněčné linie MeSH
• nádory mozku diagnóza   genetika   metabolismus   MeSH
• oprava chybného párování bází DNA * MeSH
• prediktivní hodnota testů MeSH
• studie případů a kontrol MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• DNA vazebné proteiny MeSH
• enzymy opravy DNA MeSH
• G-T mismatch-binding protein MeSH Prohlížeč
• homolog 2 proteinu MutS MeSH
• mismatch repair endonukleáza PMS2 MeSH
• MLH1 protein, human MeSH Prohlížeč
• MSH2 protein, human MeSH Prohlížeč
• MutL homolog 1 MeSH
• nádorové biomarkery MeSH
• PMS2 protein, human MeSH Prohlížeč

Multiple familial trichoepitheliomas (MFT) is an autosomal dominantly inherited disease characterized by multiple skin appendage tumors. We describe a patient showing a continuous spectrum of follicular differentiated neoplasms including classical trichoepitheliomas but also infiltrative growing and finally metastasizing malignant follicular differentiated tumors. Germline mutation analysis revealed a nonsense mutation in the cylindromatosis (CYLD) gene. Gene expression analysis by real-time PCR of tumor tissue showed overexpression of glioma-associated oncogene Gli1 mRNA. Treatment with the Hedgehog pathway inhibitor vismodegib resulted in a significant regression of the highly differentiated trichoepitheliomas. Gli upregulation is indicative of an active Hedgehog signaling pathway. We hypothesize that its upregulation is indirectly caused by CYLD mutation which promotes tumor development. Vismodegib treatment could thus provide a new treatment option for patients with this debilitating disorder.

• Klíčová slova
• Brooke syndrome, CYLD, Hedgehog pathway, Trichoepithelioma, Vismodegib,
• MeSH
• anilidy terapeutické užití   MeSH
• antitumorózní látky terapeutické užití   MeSH
• dědičné nádorové syndromy farmakoterapie   genetika   metabolismus   patologie   MeSH
• dědičnost MeSH
• deubikvitinizační enzym CYLD genetika   MeSH
• fenotyp MeSH
• genetická predispozice k nemoci MeSH
• imunohistochemie MeSH
• lidé středního věku MeSH
• lidé MeSH
• nádory kůže farmakoterapie   genetika   metabolismus   patologie   MeSH
• nesmyslný kodon MeSH
• počítačová rentgenová tomografie MeSH
• protein Gli1 genetika   metabolismus   MeSH
• pyridiny terapeutické užití   MeSH
• rodokmen MeSH
• signální transdukce účinky léků   MeSH
• upregulace MeSH
• výsledek terapie MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• kazuistiky MeSH
• Názvy látek
• anilidy MeSH
• antitumorózní látky MeSH
• CYLD protein, human MeSH Prohlížeč
• deubikvitinizační enzym CYLD MeSH
• GLI1 protein, human MeSH Prohlížeč
• HhAntag691 MeSH Prohlížeč
• nesmyslný kodon MeSH
• protein Gli1 MeSH
• pyridiny MeSH

Cutaneous cylindroma is an adnexal tumour with apocrine differentiation. A predisposition to multiple cylindromas is seen in patients with Brooke-Spiegler syndrome, who carry germline mutations in the tumour suppressor gene CYLD. Previous studies of inherited cylindromas have highlighted the frequent presence of bi-allelic truncating CYLD mutations as a recurrent driver mutation. We have previously shown that sporadic cylindromas express either MYB-NFIB fusion transcripts or show evidence of MYB activation in the absence of such fusions. Here, we investigated inherited cylindromas from several families with germline CYLD mutations for the presence of MYB activation. Strikingly, none of the inherited CYLD-defective (n = 23) tumours expressed MYB-NFIB fusion transcripts. However, MYB expression was increased in the majority of tumours (69%) and global gene expression analysis revealed that well-established MYB target genes were up-regulated in CYLD-defective tumours. Moreover, knock-down of MYB expression caused a significant reduction in cylindroma cell proliferation, suggesting that MYB is also a key player and oncogenic driver in inherited cylindromas. Taken together, our findings suggest molecular heterogeneity in the pathogenesis of sporadic and inherited cutaneous cylindromas, with convergence on MYB activation. © 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

• Klíčová slova
• CYLD, MYB, MYB-NFIB, adenoid cystic carcinoma, cylindroma, gene fusion, germline mutation,
• MeSH
• dědičné nádorové syndromy genetika   metabolismus   patologie   MeSH
• deubikvitinizační enzym CYLD MeSH
• dospělí MeSH
• fenotyp MeSH
• fúzní onkogenní proteiny genetika   metabolismus   MeSH
• genotyp MeSH
• hybridizace in situ fluorescenční MeSH
• lidé středního věku MeSH
• lidé MeSH
• nádorové supresorové proteiny genetika   metabolismus   MeSH
• nádory kůže genetika   metabolismus   patologie   MeSH
• proliferace buněk MeSH
• sekvenční analýza DNA MeSH
• sekvenční analýza hybridizací s uspořádaným souborem oligonukleotidů MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• stanovení celkové genové exprese MeSH
• zárodečné mutace * MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• CYLD protein, human MeSH Prohlížeč
• deubikvitinizační enzym CYLD MeSH
• fúzní onkogenní proteiny MeSH
• MYB-NFIB fusion protein, human MeSH Prohlížeč
• nádorové supresorové proteiny MeSH

Anticancer effect of heat shock, either alone or in combination with the drug PMEDAP, and cold water immersion stress were studied in an in vivo model of s.c. transplanted rat T-cell lymphomas in an inbred Sprague-Dawley rat line (SD/cub). Significant anticancer effect was induced by repeated sessions of heat shock; decrease of s.c. lymphoma weight and prolongation of survival time of treated rats was found to be dependent on the number of HS sessions. Much stronger therapeutic effect was observed after repeated heat shock in combination with PMEDAP administration. Light and electron microscopy studies were performed to characterize the alterations within the lymphomas. Morphologically, cellular alterations corresponding with apoptosis were observed in lymphoma cells after repeated heat shock. Indirect immunoperoxidase technique was used to detect HSP 72/73 protein(s), p53 and Bcl2 proteins in lymphomas heated directly or indirectly. The induction of HSP 72/73 protein(s) was found in the lymphoma tissues from autopsied animals exposed to heat shock; the intensity of its expression was dependent on the experimental design. The expression of p53 and BcL2 proteins was not changed in lymphoma cells of HS treated animals as compared to that of untreated lymphoma bearing controls; the Bcl2 protein was present in both treated and untreated lymphomas, and the p53 protein remained undetectable in all samples. Contrary to the heat shock, the cold stress did not suppress growth of lymphomas and, furthermore, accelerated the infiltration of parenchymatous organs with lymphoma cells.

• MeSH
• adenin analogy a deriváty   terapeutické užití   MeSH
• antimetabolity antitumorózní terapeutické užití   MeSH
• apoptóza MeSH
• dědičné nádorové syndromy farmakoterapie   metabolismus   patologie   terapie   MeSH
• fyziologický stres patologie   MeSH
• indukovaná hypertermie * MeSH
• kombinovaná terapie MeSH
• kryoterapie MeSH
• krysa rodu Rattus MeSH
• lymfom T-buněčný farmakoterapie   genetika   metabolismus   patologie   terapie   MeSH
• nádorové proteiny analýza   MeSH
• nádorový supresorový protein p53 analýza   MeSH
• ponoření MeSH
• potkani Sprague-Dawley MeSH
• proteiny tepelného šoku HSP72 MeSH
• proteiny tepelného šoku analýza   MeSH
• protoonkogenní proteiny c-bcl-2 analýza   MeSH
• tělesná hmotnost MeSH
• transplantace nádorů MeSH
• zvířata MeSH
• Check Tag
• krysa rodu Rattus MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• srovnávací studie MeSH
• Názvy látek
• 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine MeSH Prohlížeč
• adenin MeSH
• antimetabolity antitumorózní MeSH
• nádorové proteiny MeSH
• nádorový supresorový protein p53 MeSH
• proteiny tepelného šoku HSP72 MeSH
• proteiny tepelného šoku MeSH
• protoonkogenní proteiny c-bcl-2 MeSH